[1] NEWELL LF,COOK RJ.Advances in acute myeloid leukemia ［J］.BMJ,2021,375:n2026.
[2] RIETHER C,SCHURCH CM,OCHSENBEIN AF.Regulation of hematopoietic and leukemic stem cells by the immune system ［J］.Cell Death Differ,2015,22(2):187-198.
[3] BO H,GAO L,CHEN Y,et al.Upregulation of the expression of Wnt5a promotes the proliferation of pancreatic cancer cells in vitro and in a nude mouse model ［J］.Mol Med Rep,2016,13(2):1163-1171.
[4] BUGTER JM,FENDERICO N,MAURICE MM.Mutations and mechanisms of WNT pathway tumour suppressors in cancer ［J］.Nat Rev Cancer,2021,21(1):5-21.
[5] LEE HY,HONG IS.Targeting liver cancer stem cells:An alternative therapeutic approach for liver cancer ［J］.Cancers(Basel),2020,12(10):2746.
[6] NUSSE R,VARMUS H.Three decades of Wnts:a personal perspective on how a scientific field developed ［J］.EMBO J,2012,31(12):2670-2684.
[7] RODRIGUES A,COSTA R GA,SILVA S LR,et al.Cell signaling pathways as molecular targets to eliminate AML stem cells ［J］.Crit Rev Oncol Hematol,2021,160:103277.
[8] CHAE WJ,BOTHWELL ALM.Canonical and non-canonical Wnt signaling in immune cells ［J］.Trends Immunol,2018,39(10):830-847.
[9] GHOSH N,HOSSAIN U,MANDAL A,et al.The Wnt signaling pathway:a potential therapeutic target against cancer ［J］.Ann N Y Acad Sci,2019,1443(1):54-74.
[10] GRUSZKA AM,VALLI D,ALCALAY M.Wnt signalling in acute myeloid leukaemia ［J］.Cells,2019,8(11):1403.
[11] WANG Y,KRIVTSOV AV,SINHA AU,et al.The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML ［J］.Science,2010,327(5973):1650-1653.
[12] LI L,SHENG Y,LI W,et al.Beta-catenin Is a candidate therapeutic target for myeloid neoplasms with del(5q)［J］.Cancer Res,2017,77(15):4116-4126.
[13] CHONG PSY,ZHOU J,CHOOI JY,et al.Non-canonical activation of beta-catenin by PRL-3 phosphatase in acute myeloid leukemia ［J］.Oncogene,2019,38(9):1508-1519.
[14] UGARTE GD,VARGAS MF,MEDINA MA,et al.Wnt signaling induces transcription,spatial proximity,and translocation of fusion gene partners in human hematopoietic cells ［J］.Blood,2015,126(15):1785-1789.
[15] TICKENBROCK L,SCHWABLE J,WIEDEHAGE M,et al.Flt3 tandem duplication mutations cooperate with Wnt signaling in leukemic signal transduction ［J］.Blood,2005,105(9):3699-3706.
[16]］ JIANG X,MAK PY,MU H,et al.Disruption of Wnt/beta-catenin exerts antileukemia activity and synergizes with FLT3 inhibition in FLT3-mutant acute myeloid leukemia ［J］.Clin Cancer Res,2018,24(10):2417-2429.
[17] RUVOLO PP,QIU Y,COOMBES KR,et al.Phosphorylation of GSK3alpha/beta correlates with activation of AKT and is prognostic for poor overall survival in acute myeloid leukemia patients ［J］.BBA Clin,2015,4:59-68.
[18] HOU P,WU C,WANG Y,et al.A genome-wide CRISPR screen identifies genes critical for resistance to FLT3 inhibitor AC220 ［J］.Cancer Res,2017,77(16):4402-4413.
[19] GUEZGUEZ B,ALMAKADI M,BENOIT YD,et al.GSK3 deficiencies in hematopoietic stem cells initiate pre-neoplastic state that is predictive of clinical outcomes of human acute leukemia ［J］.Cancer Cell,2016,29(1):61-74.
[20] RATTI S,MONGIORGI S,RUSCIANO I,et al.Glycogen synthase kinase-3 and phospholipase C-beta signalling:Roles and possible interactions in myelodysplastic syndromes and acute myeloid leukemia ［J］.Biochim Biophys Acta Mol Cell Res,2020,1867(4):118649.
[21] CHATTERJEE R,GUPTA S,LAW S.Hematopathological alterations of major tumor suppressor cascade,vital cell cycle inhibitors and hematopoietic niche components in experimental myelodysplasia ［J］.Chem Biol Interact,2017,273:1-10.
[22] FEDER K,EDMAIER-SCHROGER K,RAWAT VPS,et al.Differences in expression and function of LEF1 isoforms in normal versus leukemic hematopoiesis ［J］.Leukemia,2020,34(4):1027-1037.
[23] MORGAN RG,RIDSDALE J,PAYNE M,et al.LEF-1 drives aberrant beta-catenin nuclear localization in myeloid leukemia cells ［J］.Haematologica,2019,104(7):1365-1377.
[24] TAKAM KAMGA P,DAL COLLO G,CASSARO A,et al.Small molecule inhibitors of microenvironmental Wnt/beta-catenin signaling enhance the chemosensitivity of acute myeloid leukemia ［J］.Cancers(Basel),2020,12(9):2696.
[25] VALDEZ BC,YUAN B,MURRAY D,et al.Enhanced cytotoxicity of bisantrene when combined with venetoclax,panobinostat,decitabine and olaparib in acute myeloid leukemia cells ［J］.Leuk Lymphoma,2022,63(7):1634-1644.
[26] ROGERS S,SCHOLPP S.Vertebrate Wnt5a-at the crossroads of cellular signalling ［J］.Semin Cell Dev Biol,2022,125:3-10.
[27] HUMPHRIES AC,MLODZIK M.From instruction to output:Wnt/PCP signaling in development and cancer ［J］.Curr Opin Cell Biol,2018,51:110-116.
[28] DAULAT AM,BORG JP.Wnt/planar cell polarity signaling:New opportunities for cancer treatment ［J］.Trends Cancer,2017,3(2):113-125.
[29] JIANG D,HE Y,MO Q,et al.PRICKLE1,a Wnt/PCP signaling component,is overexpressed and associated with inferior prognosis in acute myeloid leukemia ［J］.J Transl Med,2021,19(1):211.
[30] PREBET T,LHOUMEAU A C,ARNOULET C,et al.The cell polarity PTK7 receptor acts as a modulator of the chemotherapeutic response in acute myeloid leukemia and impairs clinical outcome ［J］.Blood,2010,116(13):2315-2323.
[31] CHEN Y,CHEN Z,TANG Y,et al.The involvement of noncanonical Wnt signaling in cancers ［J］.Biomed Pharmacother,2021,133:110946.
[32] NITZKI F,ZIBAT A,KONIG S,et al.Tumor stroma-derived Wnt5a induces differentiation of basal cell carcinoma of Ptch-mutant mice via CaMKII ［J］.Cancer Res,2010,70(7):2739-2748.
[33] LEWUILLON C,LAGUILLAUMIE MO,QUESNEL B,et al.Put in a "Ca(2+)ll" to acute myeloid leukemia ［J］.Cells,2022,11(3):543.
[34] KANG X,CUI C,WANG C,et al.CAMKs support development of acute myeloid leukemia ［J］.J Hematol Oncol,2018,11(1):30.
[35] SCHNOEDER TM,SCHWARZER A,JAYAVELU AK,et al.PLCG1 is required for AML1-ETO leukemia stem cell self-renewal ［J］.Blood,2022,139(7):1080-1097.
[36] SHORT NJ,RYTTING ME,CORTES JE.Acute myeloid leukaemia ［J］.The Lancet,2018,392(10147):593-606.